Yttrium-90
Updates to Article Attributes
Yttrium-90 (90Y) is a radioisotope; derived from the decay of 90Sr.
Yttrium-90 decays due to the emission of β- particles, with a half-life of 2.67 days. It can be used for metabolic radiopharmaceutical therapy, for example: non-Hodgkin’s B-cell lymphomaslymphoma radioimmunotherapy (radiopharmaceutical therapy and immunotherapy). The radiopharmaceutical used is 90Y-ibritumomab tiuxetan; it is a murine monoclonal antibody (mAb) directed at human CD20. Radio-yttriumRadioactive yttrium is bound to the mAb through the tiuxetan, a bifunctional chelator.
Radiosynoviorthesis
Colloidal Yttriumyttrium-90 citrate is the radiopharmaceutical used in radiosynoviorthesis (RSO), the radionuclide therapy for the treatment of joint inflammation 4.
Chemical-physical characteristics
Yttrium belongs to the group of transition metals; it has atomic number (Z) 39 and atomic weight 88.90585
Its electronic configuration is: [Kr] 4d1 5s2
The maximum energy of the emitted particles is 2.28 MeV with an average path in the human tissuses of approximately 5.8 mm. It decays in the non-radioactive isotope 90Zr.
History and etymology
Yttrium was discovered in 1794 by Johan Gadolin, a Finnish chemist, in a sample of mineral originating from Ytterby (Sweden).
-<p><strong>Yttrium-90 (<sup>90</sup>Y)</strong> is a radioisotope; derived from the decay of <sup>90</sup>Sr.</p><p>Yttrium-90 decays due to the emission of β- particles, with a half-life of 2.67 days. It can be used for metabolic radiopharmaceutical therapy, for example: non-Hodgkin’s B-cell lymphomas radioimmunotherapy (radiopharmaceutical therapy and immunotherapy). The radiopharmaceutical used is <sup>90</sup>Y-ibritumomab tiuxetan; it is a murine monoclonal antibody (mAb) directed at human CD20. Radio-yttrium is bound to the mAb through the tiuxetan, a bifunctional chelator.</p><h5>Radiosynoviorthesis </h5><p>Colloidal Yttrium-90 citrate is the radiopharmaceutical used in radiosynoviorthesis (RSO), the radionuclide therapy for the treatment of joint inflammation <sup>4</sup>.</p><h5>Chemical-physical characteristics</h5><p>Yttrium belongs to the group of transition metals; it has atomic number (Z) 39 and atomic weight 88.90585</p><p>Its electronic configuration is: [Kr] 4d1 5s2</p><p>The maximum energy of the emitted particles is 2.28 MeV with an average path in the human tissuses of approximately 5.8 mm. It decays in the non-radioactive isotope <sup>90</sup>Zr.</p><h4>History and etymology</h4><p>Yttrium was discovered in 1794 by Johan Gadolin, a Finnish chemist, in a sample of mineral originating from Ytterby (Sweden).</p><p> </p>- +<p><strong>Yttrium-90 (<sup>90</sup>Y)</strong> is a radioisotope; derived from the decay of <sup>90</sup>Sr.</p><p>Yttrium-90 decays due to the emission of β- particles, with a half-life of 2.67 days. It can be used for metabolic radiopharmaceutical therapy, for example: non-Hodgkin B-cell lymphoma radioimmunotherapy (radiopharmaceutical therapy and immunotherapy). The radiopharmaceutical used is <sup>90</sup>Y-ibritumomab tiuxetan; it is a murine monoclonal antibody (mAb) directed at human CD20. Radioactive yttrium is bound to the mAb through the tiuxetan, a bifunctional chelator.</p><h5>Radiosynoviorthesis </h5><p>Colloidal yttrium-90 citrate is the radiopharmaceutical used in radiosynoviorthesis (RSO), the radionuclide therapy for the treatment of joint inflammation <sup>4</sup>.</p><h5>Chemical-physical characteristics</h5><p>Yttrium belongs to the group of transition metals; it has atomic number (Z) 39 and atomic weight 88.90585</p><p>Its electronic configuration is: [Kr] 4d1 5s2</p><p>The maximum energy of the emitted particles is 2.28 MeV with an average path in the human tissuses of approximately 5.8 mm. It decays in the non-radioactive isotope <sup>90</sup>Zr.</p><h4>History and etymology</h4><p>Yttrium was discovered in 1794 by Johan Gadolin, a Finnish chemist, in a sample of mineral originating from Ytterby (Sweden).</p>
References changed:
- 1. Hagenbeek A. Radioimmunotherapy for NHL: Experience of 90Y-Ibritumomab Tiuxetan in Clinical Practice. Leuk Lymphoma. 2003;44 Suppl 4(sup4):S37-47. <a href="https://doi.org/10.1080/10428190310001616944">doi:10.1080/10428190310001616944</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/15154741">Pubmed</a>
- 2. Chinol M & Hnatowich D. Generator-Produced Yttrium-90 for Radioimmunotherapy. J Nucl Med. 1987;28(9):1465-70. - <a href="https://www.ncbi.nlm.nih.gov/pubmed/3625298">Pubmed</a>
- 3. Robert E. Krebs. The History and Use of Our Earth's Chemical Elements. (2006) ISBN: 9780313334382 - <a href="http://books.google.com/books?vid=ISBN9780313334382">Google Books</a>
- 1. Hagenbeek A. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice. (2003) Leukemia & lymphoma. 44 Suppl 4: S37-47. <a href="https://doi.org/10.1080/10428190310001616944">doi:10.1080/10428190310001616944</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/15154741">Pubmed</a> <span class="ref_v4"></span>
- 2. Chinol M, Hnatowich DJ. Generator-produced yttrium-90 for radioimmunotherapy. (1987) Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 28 (9): 1465-70. <a href="https://www.ncbi.nlm.nih.gov/pubmed/3625298">Pubmed</a> <span class="ref_v4"></span>
- 3. Robert E. Krebs. The History and Use of Our Earth's Chemical Elements. (2020) <a href="https://books.google.co.uk/books?vid=ISBN9780313334382">ISBN: 9780313334382</a><span class="ref_v4"></span>
Unable to process the form. Check for errors and try again.